WESTMINSTER, CA — November 13, 2025 — Leads & Copy — BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, has announced it will host an investor webcast and conference call on Friday, November 14th, 2025, at 1:30 pm Pacific / 4:30 pm Eastern.
The event, open to the public, will review the company’s financial results for the three months ending September 30th, 2025, discuss recent milestones, and include a question-and-answer session.
To listen to the live broadcast, interested parties should visit the provided website at least 15 minutes before the scheduled start time to register and download necessary software.
Participation details are as follows:
- Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/53245
- Teleconference (Domestic): 877-545-0320
- Teleconference (International): +1-973-528-0002
- Participant Access Code: 517720
Replay information is as follows:
- Teleconference Replay Expiration: Sunday, February 14th, 2027
- Teleconference Replay (Domestic): 877-481-4010
- Teleconference Replay (International): 919-882-2331
- Replay Passcode: 53245
The webcast replay and presentation materials will be available on the Investor Relations section of BioLargo’s website.
BioLargo, Inc. (OTCQX:BLGO) is described as a cleantech and life sciences innovator and engineering services solution provider. Its core products address PFAS contamination, advance water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious diseases. The company’s approach involves inventing or acquiring novel technologies, developing them into product offerings, and extending their commercial reach through licensing and channel partnerships.
Dennis P. Calvert is the President and CEO of BioLargo, Inc. and can be reached at 888-400-2863.
This press release contains forward-looking statements subject to risks and uncertainties detailed in the company’s filings with the SEC.
Source: BioLargo, Inc
